Rapport Therapeutics (RAPP) Expected to Announce Earnings on Monday

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.09. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rapport Therapeutics Trading Down 3.1%

Shares of RAPP stock traded down $0.26 during trading hours on Friday, hitting $8.25. The company's stock had a trading volume of 10,820 shares, compared to its average volume of 173,800. The stock has a market cap of $301.11 million and a PE ratio of -2.39. Rapport Therapeutics has a 12-month low of $6.43 and a 12-month high of $29.74. The company has a 50 day moving average of $10.08 and a 200 day moving average of $14.05.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citizens Jmp began coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They set a "mkt outperform" rating on the stock. JMP Securities initiated coverage on Rapport Therapeutics in a report on Tuesday, April 8th. They set a "market outperform" rating and a $28.00 target price on the stock. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.67.

Insider Activity

In other Rapport Therapeutics news, Director Wendy B. Young bought 6,000 shares of the stock in a transaction on Wednesday, March 12th. The shares were bought at an average price of $10.21 per share, with a total value of $61,260.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at $61,260. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Troy A. Ignelzi purchased 9,900 shares of the stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the transaction, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here.

Hedge Funds Weigh In On Rapport Therapeutics

Hedge funds have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new stake in shares of Rapport Therapeutics in the 1st quarter valued at approximately $2,039,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Rapport Therapeutics by 86.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock worth $99,000 after acquiring an additional 4,582 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock valued at $144,000 after acquiring an additional 4,109 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.